

# Lithium Policy

<b>Document Reference No.</b>	KMPT.CliG.182.02
<b>Replacing document</b>	KMPT.CliG.182.01
<b>Target audience</b>	Trust wide, all clinical staff
<b>Author</b>	Dr. Soundararajan Munuswamy Lola Ogungbangbe
<b>Group responsible for developing document</b>	Drug and Therapeutics Group
<b>Status</b>	Authorised
<b>Authorised/Ratified By</b>	Trust Wide Patient Safety and Mortality Review Group
<b>Authorised/Ratified On</b>	November 2020
<b>Date of Implementation</b>	November 2020
<b>Review Date</b>	November 2023
<b>Review</b>	This document will be reviewed prior to review date if a legislative change or other event otherwise dictates.
<b>Distribution date</b>	December 2020
<b>Number of Pages</b>	23
<b>Contact Point for Queries</b>	<a href="mailto:kmpt.policies@nhs.net">kmpt.policies@nhs.net</a>
<b>Copyright</b>	Kent and Medway NHS and Social Care Partnership Trust 2020

## DOCUMENT TRACKING SHEET

### Lithium Policy

Version	Status	Date	Issued to/approved by	Comments
0.1	Draft	31.7.2019	D&T for review	Approved
1.0	Final	29.10.2019	Trust Wide Patient Safety and Mortality Review Group	Ratified
1.1	Draft	06.10.2020	D&T for review	Approved
2.0	Draft	04.11.2020	Trust Wide Patient Safety and Mortality Review Group	Additional information on lithium levels specific to elderly

### REFERENCES

<p>British Association for Psychopharmacology (BAP 2016). Evidence-based guidelines for treating bipolar disorder: Revised 3<sup>rd</sup> edition recommendations.</p> <p>British National Formulary (online) London: BMJ Group and Pharmaceutical Press. Available at: <a href="https://bnf.nice.org.uk">https://bnf.nice.org.uk</a>&gt; [Accessed 20/09/2020]</p> <p>Department of Health &amp; Social Care. Supply Disruption Alert: Lithium carbonate (Priadel®) 200mg and 400mg modified release tablets – Supply Disruption. Issued:21/08/2020</p> <p>National Institute for Health and Care Excellence (NICE). Bipolar disorder: assessment and management. Clinical Guideline 185. London: NICE 2014</p> <p>National Institute for Health and Care Excellence (NICE). Antenatal and postnatal mental health: clinical management and service guidance. Clinical Guideline 192. London: NICE 2014.</p> <p>National Patient Safety Agency (NPSA) Alerts Summary Lithium December 2009  <a href="https://www.sps.nhs.uk/wp-content/uploads/2018/02/2009-NRLS-0921-Safer-lithium-tmation-2010.01.12-v1.pdf">https://www.sps.nhs.uk/wp-content/uploads/2018/02/2009-NRLS-0921-Safer-lithium-tmation-2010.01.12-v1.pdf</a> [accessed 24 August 2020]</p> <p>National Pharmacy Association. Lithium SOP: Supplying Lithium Therapy. London. Available at: <a href="https://www.npa.co.uk/wp-content/uploads/2015/import/Supplying-lithium-therapy-SOP.doc">https://www.npa.co.uk/wp-content/uploads/2015/import/Supplying-lithium-therapy-SOP.doc</a> [accessed 24 August 2020]</p> <p>Taylor D, Barnes TRE, Young AH. (2018) The Maudsley Prescribing Guidelines in Psychiatry : Bipolar disorder. 13th Edition. Oxford: Wiley-Blackwell</p>
--

### RELATED POLICIES/PROCEDURES/protocols/forms/leaflets

Medicines Management Policy	KMPT.CliG.08
Physical Health & Examination Policy	KMPT.CliG.026
Venepuncture Policy	KMPT.CliG.079
Care Pathway and CPA Policy	KMPT.CliG.001
Consent to Examination or Treatment	KMPT.CliG.049
DNA Policy	KMPT.CliG.014
Standard Universal Precautions	KMPT.CliG.089
Infection Prevention & Control Policy	KMPT.CliG.005

## SUMMARY OF CHANGES

<b>Date</b>	<b>Author</b>	<b>Page</b>	<b>Changes (brief summary)</b>
October 2020	Lola Ogungbangbe	3	Guidance on maintenance therapy added
October 2020	Lola Ogungbangbe	6-7	Information on side effects and managing lithium toxicity added
October 2020	Lola Ogungbangbe	9-11	Outline of the responsibilities of healthcare professionals in both inpatient and outpatient settings added
October 2020	Lola Ogungbangbe	12	New guidance around discharging lithium patients to primary care added
October 2020	Lola Ogungbangbe	18	New appendix 1: Lithium counselling checklist
October 2020	Lola Ogungbangbe	19	New appendix 2: Interpreting lithium levels
October 2020	Lola Ogungbangbe	20	New appendix 3: A quick reference guide/flowchart for what to do when lithium levels are at different levels.
October 2020	Lola Ogungbangbe	21	New appendix 4: lithium side effect scale.
October 2020	Lola Ogungbangbe	23	New appendix 5 lithium monitoring requirements

## CONTENTS

1	INTRODUCTION.....	1
2	WHO DOES THIS POLICY APPLY TO?.....	1
3	PURPOSE .....	1
4	DUTIES.....	1
5	BACKGROUND.....	2
6	STARTING LITHIUM THERAPY .....	2
7	MAINTENANCE LITHIUM THERAPY .....	3
8	MONITORING REQUIREMENTS OF LITHIUM THERAPY .....	5
9	LITHIUM TOXICITY .....	6
10	SIDE EFFECTS OF LITHIUM .....	7
11	LITHIUM IN PREGNANCY AND BREASTFEEDING.....	7
12	DRUG –DRUG AND DRUG- DISEASE INTERACTIONS .....	8
13	STOPPING LITHIUM THERAPY .....	9
14	MANAGEMENT OF PATIENTS ON LITHIUM IN INPATIENT SETTINGS .....	9
15	MANAGEMENT OF PATIENTS ON LITHIUM IN OUTPATIENT SETTINGS .....	11
16	TRANSFER OF CARE .....	12
17	DISCHARGING PATIENTS ON LITHIUM TO PRIMARY CARE.....	13
18	PATIENT INFORMATION .....	13
19	IMPLEMENTATION INCLUDING TRAINING AND AWARENESS.....	14
20	STAKEHOLDER, CARER AND USER INVOLVEMENT.....	14
21	EQUALITY IMPACT ASSESSMENT SUMMARY .....	14
22	HUMAN RIGHTS .....	14
23	MONITORING COMPLIANCE WITH AND EFFECTIVENESS OF THIS DOCUMENT .....	14
24	EXCEPTIONS.....	15
	APPENDIX 1: LITHIUM COUNSELLING CHECKLIST.....	16
	APPENDIX 2: INTERPRETING LITHIUM SERUM LEVELS.....	17
	APPENDIX 3: LITHIUM LEVEL FLOWCHART.....	18
	APPENDIX 4: LITHIUM SIDE EFFECTS RATING SCALE (LISERS).....	19
	APPENDIX 5: LITHIUM MONITORING REQUIREMENTS .....	20
	APPENDIX 6: MANAGING LITHIUM DRUG INTERACTIONS OR DRUG-DISEASE INTERACTION .....	22

## **1 INTRODUCTION**

- 1.1 Lithium is a well-established drug in the treatment of bipolar disorder, it is recommended as a first line long-term treatment for bipolar disorder by the National Institute for Health and Care Excellence (NICE CG 185). It is also licensed for the treatment and prophylaxis of recurrent depression, and aggressive or self-harming behaviour, and used off-license in the treatment of cluster headaches.

## **2 WHO DOES THIS POLICY APPLY TO?**

- 2.1 This policy applies to all clinical staff.

## **3 PURPOSE**

- 3.1 This policy has been developed to provide guidance to clinical staff on all aspects of lithium therapy. It also gives the necessary tools for effective compliance with the monitoring requirements of lithium therapy.
- 3.2 It provides information on the safe management of patients on lithium therapy in both inpatient and outpatient settings.
- 3.3 It outlines the responsibilities of medical, nursing and pharmacy staff.

## **4 DUTIES**

- 4.1 The trust board is accountable for
- 4.1.1 Delegating responsibility to the trust wide Clinical Governance group to ensure that the lithium policy is in force, current and reviewed regularly.
- 4.2 The Drugs and Therapeutics group is responsible for:
- 4.2.1 Development and monitoring of the lithium policy to reflect current practice within the Trust and national guidelines.
- 4.3 Chief Executive:
- 4.3.1 Has overall responsibility for the safe and secure handling of medicines.
- 4.4 Medical Director:
- 4.4.1 Is executive lead for medicines management.
- 4.4.2 Is responsible for reporting to the Trust Board on performance in relation to medicines management.
- 4.5 Chief Pharmacist:
- 4.5.1 Is accountable for establishing and maintaining a safe and secure system for medicines management throughout the Trust.
- 4.5.2 Is responsible for reporting to Trust wide Clinical Governance Group in relation to medicines management.
- 4.6 Clinical Directors/Leads and Service Directors/Leads
- 4.6.1 Are responsible for ensuring that their staff are aware.

## **5 BACKGROUND**

- 5.1 Lithium is a naturally occurring alkali metal, its salts; namely lithium carbonate and lithium citrate, are commonly used to treat a wide range of mental illnesses.
- 5.2 Lithium salts have a narrow therapeutic range and therefore dosing is governed by lithium serum levels and clinical response. Inadequate monitoring of lithium serum levels can result in lithium toxicity, which can cause significant harm to patients.
- 5.3 The National Patient Safety Agency (NPSA) in 2009, now known as NHS Improvement, identified sub-optimal monitoring and poor patient education on lithium side effects and symptoms of toxicity as key issues affecting the safe management of patients on lithium therapy. In its patient safety alert, titled “safer lithium therapy” it made a number of recommendations:
  - 5.3.1 Patients prescribed lithium are monitored in accordance with NICE guidance.
  - 5.3.2 There are reliable systems to ensure blood test results are communicated between laboratories and prescribers.
  - 5.3.3 At the start of lithium therapy and throughout their treatment patients receive appropriate ongoing verbal and written information and a record book to track lithium blood levels and relevant clinical tests.
  - 5.3.4 Prescribers and pharmacists check that blood tests are monitored regularly and that it is safe to issue a repeat prescription and/or dispense the prescribed lithium.
  - 5.3.5 Systems are in place to identify and deal with medicines that might adversely interact with lithium therapy.

## **6 STARTING LITHIUM THERAPY**

- 6.1 All patients being considered for lithium therapy should be provided with written and verbal information on lithium; encompassing the monitoring requirements, side effects, and potential therapeutic benefits, to allow the patient to engage in the decision making process.
- 6.2 Patients and carers where applicable, should have a clear understanding of who will be responsible for their care and carrying out the monitoring requirements.
- 6.3 Prior to prescribing lithium, the following baseline tests and measurements should be carried out:
  - 6.3.1 Renal Function Tests i.e. eGFR or CrCL
  - 6.3.2 Urea and Electrolytes (U&Es) including corrected calcium
  - 6.3.3 Thyroid Function Tests (TFTs)
  - 6.3.4 Full Blood Count (FBC)
  - 6.3.5 Fasting blood glucose, glycosylated haemoglobin (HbA1c) and blood lipid profile
  - 6.3.6 Weight, BMI and waist circumference
  - 6.3.7 ECG to be done for people with cardiovascular disease or risk factors for it

- 6.4 Before prescribing lithium check the Summary of Product Characteristics (SPC) to ensure there are no contraindications to the patient starting lithium.
  - 6.4.1 Start lithium carbonate at 400mg daily for adults, for elderly patients, those with conditions, or taking medications, that put them at high risk of lithium toxicity consider starting lithium carbonate at 200mg-250mg daily.
- 6.5 When prescribing lithium, ensure brand name and formulation are specified, as not all brands are bioequivalent.
  - 6.5.1 specify if the preparation is modified release
- 6.6 Note tablet formulations contain lithium carbonate and the liquid formulations contain lithium citrate
  - 6.6.1 **Lithium carbonate 200mg tablet** is approximately equivalent to **509mg/520mg lithium citrate liquid.**
- 6.7 Ensure the patient is given a lithium booklet, and their target serum level is specified in the booklet.
- 6.8 On starting lithium measure lithium serum levels weekly until a stable serum levels is achieved.
  - 6.8.1 Levels can be done after 5 days if preferable
- 6.9 Dose of Lithium may be adjusted at weekly interval in accordance with serum lithium levels, until the desired therapeutic serum levels or clinical response is achieved.
- 6.10 Serum levels should be measured weekly after each dose change until a stable serum levels is achieved.
- 6.11 Record the serum levels result in the patient's Lithium booklet and in patient's notes.
- 6.12 A serum lithium level between 0.6 and 0.8 mmol/l should be targeted in patients being treated with lithium for the first time.
  - 6.12.1 In elderly patients, lower serum lithium levels (e.g. <0.6mmol) may be adequate and the target range should be based on response.
- 6.13 Consider maintaining serum lithium levels at 0.8–1.0 mmol per litre for a trial period of at least 6 months for people who:
  - 6.13.1 Have had a relapse while taking lithium in the past or
  - 6.13.2 Are taking lithium and have subthreshold symptoms with functional impairment.

## 7 MAINTENANCE LITHIUM THERAPY

- 7.1 Once a stable lithium serum level has been achieved for a specific dose, lithium serum levels should be monitored every 3 months for the first year of treatment, then every 6 months thereafter.
- 7.2 For patients in the following groups, NICE recommends serum lithium level is measured at 3 monthly interval:
  - 7.2.1 Older people
  - 7.2.2 People taking drugs that interact with lithium
  - 7.2.3 People who are at risk of impaired renal or thyroid function, raised calcium levels or other complications

- 7.2.4 People who have poor symptom control
  - 7.2.5 People with poor adherence
  - 7.2.6 People whose last serum lithium level was 0.8 mmol/l or higher
- 7.3 A therapeutic range of 0.6–0.8 mmol/L should be aimed for in patients being treated with lithium for the first time. Lithium levels above 0.8mmol/L are associated with an increased risk of renal impairment (BAP 2016)
- 7.3.1 In elderly patients, lower serum lithium levels (e.g. <0.6mmol) may be adequate and the target range should be based on response.
- 7.4 Consider maintaining serum lithium levels at 0.8–1.0 mmol per litre for a trial period of at least 6 months for people who:
- 7.4.1 Have had a relapse while taking lithium in the past or
  - 7.4.2 Are taking lithium and have subthreshold symptoms with functional impairment.
- 7.5 Serum levels above 1mmol/l require medical review, particularly if this has not been explicitly stated as a desired therapeutic lithium range.
- 7.6 Where a consultant deems a level above 1mmol/l is more clinically appropriate for a patient, this must be care planned and documented in the patient's notes; providing a clear rationale for the target range and the risks associated with lithium levels above 1mmol/l.
- 7.7 Such patients should be counselled on the signs of lithium toxicity and provided with a clear care pathway, in the event symptoms of toxicity arise.
- 7.8 In these patients lithium levels should be monitored more frequently e.g. monthly and upper acceptable limits should be clearly defined in the patient's notes and recorded in the patient's lithium booklet.
- 7.9 When reviewing patients on lithium the following steps should take place:
- 7.9.1 Review the latest lithium serum levels
  - 7.9.2 Review Lithium booklet and update the booklet where required
    - a) Issue a booklet if the patient does not have one
  - 7.9.3 Ensure all monitoring requirements are being complied with
  - 7.9.4 Check for interactions with newly prescribed medication
  - 7.9.5 Screen for lithium toxicity symptoms e.g. neurotoxicity, including paraesthesia, ataxia, tremor and cognitive impairment
  - 7.9.6 Reiterate the key counselling points to patients
  - 7.9.7 Check patient's understanding of lithium therapy and address any knowledge gaps
  - 7.9.8 Check for newly diagnosed illnesses
- 7.10 When patients become physically ill or when they are started on medications with propensity to affect the clearance of lithium, extra vigilance and increased monitoring is required.

- 7.11 Carry out a side effects assessment every 6 months (see Appendix 4 for the liser scale)

## **8 MONITORING REQUIREMENTS OF LITHIUM THERAPY**

### **8.1 Serum lithium level**

8.1.1 Serum lithium levels should be measured weekly on initiation of treatment and following a dose change, until a stable serum level is achieved, then every 3 months, after a year on lithium therapy serum levels can be carried out every 6 months, except for certain groups of patients (refer to section 7.2).

8.1.2 More frequent tests should be carried out if there is evidence of clinical deterioration, abnormal results, a change in sodium intake, or symptoms suggesting abnormal renal or thyroid function such as unexplained fatigue, if the patient is starting medication such as ACE inhibitors, NSAIDs, or diuretics.

8.1.3 Monitor serum lithium levels more frequently if urea levels and creatinine levels become elevated, or eGFR falls over 2 or more tests, and assess the rate of deterioration of renal function.

8.1.4 If a patient is switched from one brand of lithium to another, serum lithium levels should be monitored closely in a similar fashion to initiation of treatment (i.e. weekly until levels stabilised) and the patient should be monitored for signs of relapse and adverse effects in the initial period.

a) baseline serum lithium level should be taken prior to switching

8.1.5 Lithium serum levels should be measured 12 hours post dose (range 11-13 hours post-dose), this is usually in the morning for a night time dosing.

8.1.6 For patients on a twice daily regimen, sample should be taken before the morning dose is taken.

8.1.7 For most patients a serum level between 0.6-0.8mmol/l will be adequate, however some patients may require levels closer to 1mmol/l. Likewise some patients may respond to levels below 0.6mmol/l.

8.1.8 For interpretation of serum lithium levels, see appendix 2

8.2 The following tests/measures should be conducted every 6 months during maintenance treatment:

8.2.1 Renal function tests (e-GFR or CrCL)

8.2.2 Urea & Electrolytes including corrected calcium

8.2.3 Thyroid function tests

8.2.4 Weight or BMI

8.3 Conduct above tests more often if there is evidence of impaired renal or thyroid function, raised calcium levels or an increase in mood symptoms that might be related to impaired thyroid function.

8.4 The following tests/measures should be conducted at least every year during maintenance treatment:

- Fasting blood glucose, glycosylated haemoglobin (HbA1c)
- blood lipid profile
- cardiovascular status, including pulse and blood pressure
  - ECG for people with cardiovascular disease or risk factors for it.

## 9 LITHIUM TOXICITY

9.1 Lithium toxicity tends to occur when serum levels exceed 1mmol/L but can also occur within the normal therapeutic range, especially in the elderly. Signs and symptoms of toxicity are reliably seen at levels  $\geq 1.5$ mmol/l and can be life threatening, symptoms include:

- Fine tremor increasing to coarse tremor
- Blurred vision
- Ataxia
- Slurred speech
- Vomiting and diarrhoea
- Severe polyuria
- Confusion
- Seizures
- Renal damage may also occur

9.2 If any of these symptoms are experienced by a patient, lithium therapy should be stopped immediately and lithium levels checked urgently.

9.3 Restarting lithium after lithium toxicity:

9.3.1 Assess the likelihood of another lithium toxicity event.

9.3.2 If lithium toxicity occurred as a result of overdose, assess if patient still at high risk of overdose and evaluate if the potential benefit of lithium outweighs risk, taking into account the severity of the patient's illness.

9.3.3 Explore steps that can be taken to reduce the risk or impact of another overdose event.

e.g.. limit supply of medication or medication in custody of carers.

9.3.4 Before restarting lithium, ensure level has fallen below a toxic level, ideally to a mid-range therapeutic level e.g. 0.7mmol/l

9.3.5 Consider re-starting at a dose lower than the previous dose and monitor serum lithium level weekly until level stabilised.

a) may not be necessary if toxicity is due to overdose

9.3.6 Avoid or minimise the impact of drugs that may contribute to lithium toxicity e.g. Diuretics, NSAIDs, ACEI

9.3.7 Advise patient to report any changes in physical health status e.g. diarrhoea, vomiting, UTI

9.3.8 Consider an increased monitoring frequency e.g. monthly for the 1<sup>st</sup> three months before switching to a 3 monthly serum level monitoring.

## **10 SIDE EFFECTS OF LITHIUM**

10.1 Lithium has a wide range of side effects. Many of these are related to the serum levels, and it may be possible to manage some of these by adjusting the dose. It is important the patient is counselled on these side effects when lithium is initiated and advised to speak to a healthcare professional if they have any concerns. Lithium side effects include:

- Mild gastrointestinal upset
- Fine tremor
- Weight gain
- Ankle oedema
- Metallic taste
- Nephrogenic diabetes insipidus, resulting in polydipsia and polyuria
- Renal toxicity – reduction in glomerular filtration rate
- Hypothyroidism
- Exacerbation of skin conditions, including psoriasis and acne
- Change in renal function

10.2 For a full list of side effects see the summary of product characteristics for lithium.

10.3 If there is a suspicion of lithium toxicity, serum lithium levels should be measured as soon as possible, preferably within 24hrs and the request should be marked as urgent.

## **11 LITHIUM IN PREGNANCY AND BREASTFEEDING**

11.1 Lithium has teratogenic effects; women of child-bearing age should be advised about the importance of effective contraception whilst on lithium, particularly patients with bipolar disorder, given the greater risk of unplanned pregnancy in this population.

11.2 All women on lithium who become pregnant should be referred to MIMHS as soon as feasible following confirmation of pregnancy.

11.3 Advise all pregnant women to take folate supplement

11.4 Discuss the risk of harm to the woman and the foetus associated with her mental health problem

11.5 Discuss risk associated with lithium in pregnancy with pregnant women, exposure to lithium during the first trimester is associated with a 0.05–0.1% risk of cardiovascular anomalies including Ebstein's anomaly (BAP 2016).

11.6 Discuss the risk or harm to the woman and the child associated with stopping or changing a treatment.

11.6.1 52% of women who discontinued lithium during pregnancy relapsed and 70% of the women who remained stable after lithium discontinuation during pregnancy relapsed in the post-partum period (BAP 2016)

- 11.7 Do not start lithium in women who are planning a pregnancy or pregnant, unless antipsychotic medication has not been effective.
- 11.8 Lithium should be avoided in the first trimester of pregnancy, unless benefit outweighs risk.
- 11.9 If a woman whose symptoms are well controlled becomes pregnant, consider stopping lithium gradually over a four weeks period. Explain to the woman that this may not remove the risk of cardiac defects in the foetus and there is a risk of relapse, particularly in the postnatal period.
- 11.10 For a pregnant woman that is not well or is at high risk of relapse, consider switching gradually to an antipsychotic, or stop lithium and restart it in the second trimester, provided the woman is not planning to breastfeed and her symptoms have responded better to lithium than to other drugs in the past.
- 11.11 If antipsychotic is likely to be ineffective you may consider continuing with lithium.
- 11.12 If a woman continues taking lithium during pregnancy:
  - 11.12.1 Check serum levels every 4 weeks, then weekly from the 36<sup>th</sup> week, and less than 24 hours after childbirth
  - 11.12.2 Adjust the dose to keep serum levels towards the lower end of the therapeutic range
  - 11.12.3 Advise patient to maintain adequate fluid intake.
  - 11.12.4 Women taking lithium should deliver in hospital and be monitored during labour by the obstetric team.
  - 11.12.5 Monitoring should include checking serum lithium levels and fluid balance, because of the risk of dehydration and lithium toxicity
- 11.13 Lithium should be withheld during labour and for 24-48hrs before a pre-planned caesarean section.
- 11.14 Serum lithium levels checked 12 hours after the last dose.
- 11.15 High concentrations of lithium are found in breastmilk, as a result lithium is not recommended in women who are breastfeeding.

## **12 DRUG –DRUG AND DRUG- DISEASE INTERACTIONS**

- 12.1 Certain drugs may increase the risk of lithium toxicity; these include ACEIs, ARBs, diuretics, NSAIDs, metronidazole. See Appendix 6 for a list of drugs that commonly interact with lithium.
- 12.2 Certain disease state and physical health factors are associated with increase in the risk of lithium toxicity; these include renal failure, reduced sodium intake, increased sodium loss (e.g. diarrhoea and vomiting), dehydration, and urine tract infections.

### **13 STOPPING LITHIUM THERAPY**

- 13.1 Sudden discontinuation of lithium in bipolar affective disorder is associated with relapse in up to 50% of patients (DHSC 2020)
- 13.2 Where possible lithium should be discontinued gradually, unless there is a high risk of harm to the patient, such as in lithium toxicity.
- 13.3 When stopping lithium, reduce the dose gradually over at least 4 weeks, preferably up to 3 months, even if the person has started taking another anti-manic drug.
- 13.4 Ensure the patient's GP and any other relevant persons are informed lithium has been discontinued as soon as feasible.
- 13.5 Advise patient discontinuation of lithium therapy in bipolar prophylaxis can lead to relapse.
- 13.6 During dose reduction and for 3 months after lithium treatment is stopped, monitor the person closely for early signs of mania and depression.
- 13.7 Monitoring of symptoms, mood and mental state should continue for 2 years after lithium has been stopped entirely, this may be undertaken in primary care (NICE CG 185).

### **14 MANAGEMENT OF PATIENTS ON LITHIUM IN INPATIENT SETTINGS**

- 14.1 For patients initiated on lithium during admission follow the steps outlined in section 6 of this policy.
- 14.2 All healthcare professionals involved in the care of patients on lithium should be aware of the common signs and symptoms of lithium toxicity.
- 14.3 All healthcare professionals should ensure patients prescribed lithium have a lithium booklet.

#### **Doctors and Prescriber's Responsibilities**

(refer to section 8 in addition to below)

- 14.4 Ask newly admitted patients on lithium, during admission clerk in, for their booklet to gain an overview of serum lithium level history and to ensure compliance with mandatory monitoring requirements.
- 14.5 Check history of compliance with lithium.
- 14.6 Confirm lithium dose, brand and formulation using at least two sources (e.g. patient, SCR, electronic patients notes, carers) and prescribe accordingly.
- 14.7 Serum lithium levels should be measured within 24hrs of admission or next working day; the sample should be taken 12 hours after the patient's last dose.
- 14.8 Where there's a suspicion of lithium toxicity, sample should be taken urgently irrespective of the time of last dose, and lithium withheld until result available.

- 14.8.1 Collect sample in yellow top bottles, and mark sample as urgent where toxicity is suspected
- 14.9 If the patient hasn't had a dose for over 12hrs, the sample should be taken as soon as possible. The time that has elapsed since patient's last dose of lithium should be taken into consideration when interpreting result.
- 14.10 In addition to serum lithium level, carry out the other required mandatory tests/measurements for lithium therapy, these include
- U&Es including Ca<sup>2+</sup>
  - TFT,
  - RFT
- 14.11 Tests result to be promptly chased up by the requesting practitioner, or handed over to the practitioner next on duty to chase up, and recorded in patient's notes. For interpretation of lithium levels see Appendix 2
- 14.12 Be aware of conditions that may predispose to lithium toxicity
- 14.13 Consider initiating a fluid chart for patients on lithium therapy to encourage adequate fluid intake, where there are issues with fluid intake.
- 14.14 Be aware of the common signs and symptoms of lithium toxicity and screen for lithium toxicity at each consultation.
- 14.15 At discharge, ensure the following is included in the discharge summary:
- 14.15.1 latest serum lithium levels.
  - 14.15.2 frequency of serum lithium monitoring and other mandatory tests
  - 14.15.3 target therapeutic lithium range.
  - 14.15.4 brand of lithium the patient takes

### **Pharmacy staff responsibilities**

- 14.16 Pharmacy team to obtain latest serum lithium levels result when carrying out medicines reconciliation on admission and document in the relevant section of the medicines reconciliation form.
- 14.17 Review the drug chart (or electronic prescription where in use) and ensure lithium has been prescribed correctly on the drug chart, highlight any discrepancies to doctors or non-medical prescriber (NMP)
- 14.18 Check for drug interactions and discuss any concerns with ward doctors or NMP
- 14.19 Check if lithium booklet has been updated with admission blood and therapeutic target range specified in booklet.
- 14.20 Pharmacy staff to ensure all mandatory monitoring requirements are being complied with.
- 14.21 Endorse the drug chart or electronic prescription with the latest serum lithium level.

- 14.22 Issue a lithium booklet to all patients who do not have one and endorse chart to indicate lithium booklet has been supplied.
- 14.23 Pharmacy team to counsel patients on lithium therapy and record consultation in patient's notes; highlighting the key points discussed during consultation (see appendix 1)
- 14.24 Pharmacy team to ensure lithium booklet is updated with relevant results prior to discharge.

### **Nursing Staff Responsibilities**

- 14.25 Nursing team to note down any safety concerns (e.g. poor fluid intake, outstanding monitoring) about patients on lithium in their ward management plan (e.g. Meridian) and highlight to the medical team.
- 14.26 Be aware of the common signs and symptoms of lithium toxicity and side effects (see **section 9 and 10**)
- 14.27 The information that a patient is on lithium should be added to their MEWS chart so that health care assistants can look out for signs of toxicity during observation.
- 14.28 Do not interchange brands of lithium; ensure the brand prescribed is administered.
- 14.29 If there is a suspicion of lithium toxicity, the nursing staff should contact the doctor on duty immediately.
- 14.30 When patients are transferred to a different ward/unit/hospital, information that they are on lithium and its monitoring requirements, along with the patient's lithium booklet should be handed over.
- 14.31 At discharge, contact should be made with the relevant CMHT lithium lead to advise of discharge.
- 14.32 Nursing team to ensure patients are given their lithium booklets on discharge.

## **15 MANAGEMENT OF PATIENTS ON LITHIUM IN OUTPATIENT SETTINGS**

- 15.1 All CMHT should have an appointed lithium lead
- 15.2 It is the responsibility of the service manager for each CMHT to ensure the lithium lead has been adequately trained.

### **Responsibilities of Lithium Leads**

- 15.3 CMHT lithium leads will proactively identify patients under the care of their respective CMHT prescribed lithium.
- 15.4 The lead will develop and maintain a register of all patients prescribed lithium under their CMHT

- 15.5 Keep a record of all the mandatory tests including serum lithium levels carried out for patients on lithium and ensure this is recorded in the appropriate section on RiO.
- 15.6 Liaise with responsible clinician/prescriber to coordinate the blood test and physical health monitoring with every CPA review meeting if the client is on CPA care pathway.
- 15.7 Highlight all abnormal results (e.g. renal function, U&Es, TFT and serum levels) to patient's consultant or prescriber.
- 15.8 Liaise with local laboratory to establish a clear line of communication in case of abnormal results relating to lithium therapy.
- 15.9 Obtain access to the pathology system of their local acute trust.

### **Responsibilities of Consultant**

- 15.10 Refer to section 6 for patients being initiated on lithium therapy
- 15.11 Refer to section 7 for ongoing therapy
- 15.12 Ensure all patients prescribed lithium have a six monthly review with a CMHT prescriber.
- 15.13 Communicate all dose changes to lithium lead and patient's GP and document in patient's notes

### **Responsibilities of Care Coordinator**

- 15.14 Advise the lithium lead of patients under their care that is prescribed lithium.
- 15.15 Be aware of the common signs and symptoms of lithium toxicity and side effects (**see section 9 and 10**)
- 15.16 Monitor patient for adherence to lithium therapy.
- 15.17 Highlight any concerns about lithium therapy to prescriber or consultant

## **16 TRANSFER OF CARE**

- 16.1 There should be handover of patient's lithium related details when a patient is being transferred from one care setting to another.
- 16.2 Prior to transfer the receiving team should check if the required brand of lithium is in stock, if not arrangement should be made to obtain this promptly.
- 16.3 When a patient is admitted to a non-psychiatric in-patient facility, the respective liaison psychiatry where available or medical team should be informed of the patient's admission and relevant information about their lithium treatment is handed over.

## **17 DISCHARGING PATIENTS ON LITHIUM TO PRIMARY CARE**

- 17.1 Establish a care arrangement with the person's GP for prescribing lithium and monitoring adverse effects, where this is available.
- 17.2 For all patients prescribed lithium who are discharged to primary care, the following information must be communicated to their GP:
  - 17.2.1 Tests and monitoring required, together with care pathway document, care plan and risk assessment
  - 17.2.2 Information on patient lithium record booklet
- 17.3 Agree the conditions under which the patient should be referred back to secondary care, examples include:
  - 17.3.1 there is a poor or partial response to treatment
  - 17.3.2 the person's functioning declines significantly
  - 17.3.3 treatment adherence is poor
  - 17.3.4 the person develops intolerable or medically important side effects from medication
  - 17.3.5 comorbid alcohol or drug misuse is suspected
  - 17.3.6 the person is considering stopping any medication after a period of relatively stable mood
  - 17.3.7 a woman with bipolar disorder is pregnant or planning a pregnancy.
- 17.4 When discharging a patient to primary care, agree a care plan with the patient, which includes:
  - 17.4.1 clear, individualised social and emotional recovery goals
  - 17.4.2 a crisis plan indicating early warning symptoms and triggers of both mania and depression relapse and preferred response during relapse, including liaison and referral pathways
  - 17.4.3 an assessment of the person's mental state
  - 17.4.4 a medication plan with a date for review by primary care, frequency and nature of monitoring for effectiveness and adverse effects, and what should happen in the event of a relapse. Give the person and their GP a copy of the plan, and encourage the person to share it with their carers.
  - 17.4.5 encourage and support the person to visit their GP and discuss the care plan before discharge and transfer.

## **18 PATIENT INFORMATION**

- 18.1 The choice and medication patient information leaflet should be provided to all patients on lithium. Staff will ensure that patient information in relation to this policy is readily available in accessible formats. This should also be given to relatives, carers and advocates where applicable.

## **19 IMPLEMENTATION INCLUDING TRAINING AND AWARENESS**

- 19.1 Managers will ensure that all relevant staff receive the appropriate training and are aware of the policy and procedure to be followed.
- 19.2 All issues relation to the safety of a patient on lithium should be reported using the Trust incident reporting policy.

## **20 STAKEHOLDER, CARER AND USER INVOLVEMENT**

- 20.1 Members of Drugs and Therapeutics Group - development, consultation and approval
- 20.2 Members of Trust Wide Patient Safety Group – consultation and ratification
- 20.3 Implementation by Global e mail/Team Brief/Medication Matters Newsletter
- 20.4 Changes to be notified by Policy manager via team brief, Intranet, “Medication Matters” Newsletter

## **21 EQUALITY IMPACT ASSESSMENT SUMMARY**

- 21.1 The Equality Act 2010 places a statutory duty on public bodies to have due regard in the exercise of their functions. The duty also requires public bodies to consider how the decisions they make, and the services they deliver, affect people who share equality protected characteristics and those who do not. In KMPT the culture of Equality Impact Assessment will be pursued in order to provide assurance that the Trust has carefully considered any potential negative outcomes that can occur before implementation. The Trust will monitor the implementation of the various functions/policies and refresh them in a timely manner in order to incorporate any positive changes.

## **22 HUMAN RIGHTS**

- 22.1 The Human Rights Act 1998 sets out fundamental provisions with respect to the protection of individual human rights. These include maintaining dignity, ensuring confidentiality and protecting individuals from abuse of various kinds. Employees and volunteers of the Trust must ensure that the trust does not breach the human rights of any individual the trust comes into contact with.

## **23 MONITORING COMPLIANCE WITH AND EFFECTIVENESS OF THIS DOCUMENT**

- 23.1 An audit will be undertaken a year following implementation and as needed, using the Trust Standards and a report submitted Clinical Effectiveness and Outgroup and Patient Safety Group

<b><i>What will be monitored</i></b>	<b><i>How will it be monitored</i></b>	<b><i>Who will monitor</i></b>	<b><i>Frequency</i></b>	<b><i>Evidence to demonstrate monitoring</i></b>	<b><i>Action to be taken in event of non compliance</i></b>
Appropriate Prescribing of Lithium Therapy	Screening of prescription	Pharmacy Team	Ongoing	<input type="checkbox"/> Screened drug charts	Provide training if required
Compliance with lithium monitoring requirements e.g. serum, eGFR	Audit of patients' record	Lithium Lead/ consultant/ pharmacy / team manager	As dictated by POMH-UK	<input type="checkbox"/> Completed audits <input type="checkbox"/> Audit Report	Provide training if required

## **24 EXCEPTIONS**

24.1 There are no exceptions


## APPENDIX 1: LITHIUM COUNSELLING CHECKLIST

Counselling points	✓ Tick ( )
Indication and potential benefits	
Plasma level monitoring and other monitoring requirements	
Side effects and symptoms of toxicity	
Lithium in pregnancy <ul style="list-style-type: none"> <li>➤ Importance of contraception</li> <li>➤ Cardiac defects e.g. Ebstein's anomaly</li> <li>➤ Inform their doctor if pregnant or are planning a pregnancy.</li> </ul>	
Importance of Adherence	
Report any changes in disease symptoms	
Conditions which could affect their lithium levels e.g dehydration	
Seek medical attention if diarrhoea, vomiting or become acutely ill for any reason e.g UTI	
Drug – Drug interaction <ul style="list-style-type: none"> <li>➤ Avoid OTC NSAIDs e.g. Ibuprofen</li> <li>➤ Inform their pharmacist when started on new medication or buying OTC</li> </ul>	
The importance of taking the lithium booklet to all appointments and the pharmacy when prescriptions are dispensed	
Importance of always taking the same brand to the patient and taking medication the same time of the day	
Lifestyle advice: <ul style="list-style-type: none"> <li>➤ maintain their fluid intake, particularly after sweating (for example, after exercise, in hot climates or if they have a fever)</li> <li>➤ Avoid drastic change in salt intake</li> </ul>	

## APPENDIX 2: INTERPRETING LITHIUM SERUM LEVELS

Lithium Serum levels	Interpretation	Comments/ required	Action
Less than 0.4mmol/l	<b>Sub-therapeutic level</b>	Note elderly patient may respond to this levels	
<b>0.4 -0.8mmol/l</b>	Therapeutic range	Adequate for most patients	
<b>0.8-1.0mmol/l</b>	Therapeutic range for acute episodes of mania, and for patients who have previously relapsed or have sub-syndromal symptoms.	Consider more frequent serum lithium monitoring	
<b>1.0-1.5mmolmol</b>	<b>High risk of lithium toxicity symptoms</b>	If no symptoms of lithium toxicity consider other explanations for the high level e.g. dehydration, timing of level i.e. not 12hrs post dose, interacting medicines. correct where possible and recheck level within 24hrs. <b>If symptoms present withhold lithium.</b>	
<b>Above 1.5 mmol/l</b>	<b>Toxic level</b>	Consider other explanations for the high level e.g. dehydration, timing of level i.e. not 12hrs post dose, interacting medicines, correct where possible.  <b>Withhold lithium immediately, repeat levels within 24hrs.</b> If level still raised, do not restart Lithium until level sufficiently below 1mmol/l and start at a lower dose	
<b>2mmol/l and above</b>	<b>Severe toxicity</b>	Urgent medical care needed, refer to And E  <b>STOP LITHIUM</b>	

**APPENDIX 3: LITHIUM LEVEL FLOWCHART**



### APPENDIX 4: LITHIUM SIDE EFFECTS RATING SCALE (LISERS)

Patient name:  
Staff Name:

D.O.B:  
Date of Assessment:

		No	Yes		
			Mild	Moderate	Severe
1	Increased appetite	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2	Increased thirst	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3	Increased output of urine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4	Weight gain	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5	Thyroid problems (check fatigue, dry skin, constipation)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6	Metallic Taste	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7	Feeling restless	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8	Dry Mouth	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9	Nausea and feeling sick	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10	Dizziness	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11	Mild tremor (fine tremor)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
12	Muscle pains and tension	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
13	Difficulties in memory	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
14	Difficulties with concentration	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
15	Feeling slowed down in my thinking and creativity	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
16	Sleep problems	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
17	Ankle oedema	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
18	Headaches	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
19	Excessive sweating	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
20	Psoriasis	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
21*	Blurred vision	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
22*	Palpitations or feeling my heart pounding	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
23*	Feeling drowsy and lethargic during the day	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
24*	Diarrhoea / vomiting	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
25*	Severe tremor (coarse tremor )	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
26*	Confusion	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
27*	Muscle weakness/ twitching	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
28*	Lack of Coordination/ unsteady on feet	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
29*	Slurred speech	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
30	Other _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

\*indicates possibility of a toxic lithium level, an urgent plasma lithium level should be carried out if any of these symptoms reported

## APPENDIX 5: LITHIUM MONITORING REQUIREMENTS

Test	Clinical reason	Frequency of test	Normal range	What to check for	What to do
Lithium serum level	Serum levels are an indication of clinical efficacy or potential toxicity. Levels should be within target range, not sub therapeutic or toxic. Toxicity has been seen at levels $\geq 1.2$ mmol/L, but it is very dependent on renal function. In elderly renally compromised patients, levels $< 1$ mmol/L have been toxic.	Once blood levels are stable, 'normally' every 3 months. Monitoring should be increased with potential drug – drug interactions, such as the introduction of thiazide diuretics.  A change in formulation should be treated as initiation of therapy for monitoring i.e weekly until stable.	Determined by prescriber and documented in the patient's lithium therapy record book. Potential range between 0.4mmol/L – 1mmol/L. NICE suggests 0.6-0.8 mmol/L as the optimum range.  Higher levels are required for patients with acute exacerbations of mania.	Levels below or above the patient's target blood level range. Also, the trend in blood levels. Progressively increasing lithium levels are a consequence of deteriorating renal function. Be more vigilant with elderly patients, or patients experiencing side effects which could be signs of toxicity.	Reassure the patient if tests are unremarkable.  Inform consultant/prescriber if out of range  Document your actions in the patient's notes  Patients with levels above 2mmol/L should be referred to Accident and Emergency.
Thyroid function tests (TFTs)	Lithium is associated with long-term risk of hypothyroidism.	Every 6 months.	Reference range varies between laboratories. Approximate normal reference ranges are: Thyroid-stimulating hormone (TSH) 0.5 – 5.5mU/L Free thyroxine (FT4) 9-19pmol/l FreeT4 is depressed with hypothyroidism. Patients with a sustained increase in TSH of greater than twice the upper limit of 'normal' (~10 mU/L) which is confirmed by repeat testing after 2 weeks should be treated with levothyroxine. A patient with a TSH which is	TSH values which are increasing and/or free T4 values that are decreasing.	Reassure the patient if tests are unremarkable. Inform consultant/prescriber if out of range  Document your actions in the patient's notes

Test	Clinical reason	Frequency of test	Normal range	What to check for	What to do
			around double the normal upper limit (~10 mU/L) or between the upper normal limit and double the normal upper limit (~5.0mU/L - ~10mU/L) may require additional monitoring and possible treatment with levothyroxine. Consult with endocrinology if in doubt.		
Estimated glomerular filtration rate (eGFR)	Measures the level of kidney function. Lithium associated with long-term risk of chronic renal impairment.	Every 6 months	Assays vary between laboratories. Values below 60 ml/min/1.73 m <sup>2</sup> are noteworthy, >90 ml/min/1.73 m <sup>2</sup> is considered normal. Renal function deteriorates with age.	An eGFR which is decreasing and/or results imply dosing adjustments should be considered.	Reassure the patient if tests are unremarkable. Inform consultant/prescriber or refer if you have concerns that renal function is deteriorating and no dose adjustments appear to have been made.  Document your actions in the patient's note
Urea and Electrolytes including corrected calcium	long-term lithium treatment is associated with persistent hyperparathyroidism and hypercalcaemia. Lithium elimination is linked to sodium levels. There is increased risk of lithium toxicity with low sodium levels.	Every 6months	Refer to local lab reference range	decreasing sodium levels (i.e below 130mmol/l). Low sodium levels may lead to lithium toxicity. Raised calcium levels may be an indication of hyperparathyroidism. Low potassium levels, as this may cause ECG changes.	Reassure the patient if tests are unremarkable. Inform consultant/prescriber if out of range  Document your actions in the patient's notes

Adapted from the NPA SOP for lithium

## APPENDIX 6: MANAGING LITHIUM DRUG INTERACTIONS OR DRUG-DISEASE INTERACTION

<b>Drug</b>	<b>Interaction effects</b>	<b>Risk Reduction measures</b>
ACE inhibitors e.g., enalapril, lisinopril Angiotensin II antagonists e.g., losartan, candesartan, valsartan	<ul style="list-style-type: none"> <li>Lithium toxicity due to sodium depletion.</li> <li>Concurrent use with caution and close monitoring.</li> <li>With Angiotensin II antagonists case reports of increase in lithium serum level.</li> </ul>	<ul style="list-style-type: none"> <li>Lithium level can increase over several weeks.</li> <li>Monitor closely for signs of lithium toxicity and consider taking lithium serum level more regularly i.e. 1 monthly rather than 3 monthly</li> <li>May need to reduce lithium dose.</li> <li>With Angiotensin II antagonists increase monitoring especially during the first couple of months.</li> </ul>
Analgesics (NSAIDs) e.g., ibuprofen, diclofenac	<ul style="list-style-type: none"> <li>Excretion of lithium reduced.</li> </ul>	<ul style="list-style-type: none"> <li>Avoid concomitant use.</li> <li>Note: low dose aspirin 75mg does not affect lithium serum levels significantly.</li> </ul>
Anti-arrhythmics e.g., amiodarone	<ul style="list-style-type: none"> <li>Increased risk of QT prolongation.</li> </ul>	<ul style="list-style-type: none"> <li>Avoid concomitant use.</li> <li>Manufacturer contraindicates combined use.</li> </ul>
Domperidone	<ul style="list-style-type: none"> <li>Lithium is associated with QT prolongation or torsade de pointes.</li> <li>Dangerous QT prolongation may occur if it is given with domperidone.</li> </ul>	<ul style="list-style-type: none"> <li>Contraindicated. Consider an alternative antiemetic.</li> </ul>
Hydroxyzine/mizolastine	<ul style="list-style-type: none"> <li>Antihistamines such as hydroxyzine and mizolastine, and lithium are associated with a small increased risk of QT prolongation.</li> <li>Concurrent use may increase the risk.</li> </ul>	<ul style="list-style-type: none"> <li>Consider an alternative antihistamine.</li> </ul>
Methyldopa	<ul style="list-style-type: none"> <li>Neurotoxicity may occur without increasing lithium serum concentration.</li> </ul>	<ul style="list-style-type: none"> <li>Avoid concomitant use if possible.</li> </ul>
Thiazide Diuretics e.g., bendroflumethiazide	<ul style="list-style-type: none"> <li>Increase lithium serum levels, therefore increased risk of lithium toxicity.</li> <li>This is a well-established and potentially serious interaction.</li> </ul>	<ul style="list-style-type: none"> <li>Avoid if possible. Other diuretics may be safer such as loop diuretics.</li> <li>Consider a lithium dose reduction and monitor lithium serum levels more regularly .</li> </ul>
Alcohol	<ul style="list-style-type: none"> <li>Increased tremor/shakiness with chronic alcohol use.</li> </ul>	<ul style="list-style-type: none"> <li>Alcohol should be avoided in the first month or two after starting lithium. After this alcohol can be drunk in moderation e.g. 1 to 2 units three time a week but ideally advise patient to reduce intake of alcohol as much as possible. This is because lithium and alcohol combination may increase risk of drowsiness.</li> </ul>
Antibiotics e.g., metronidazole, tetracycline,	<ul style="list-style-type: none"> <li>Reduced lithium excretion leading to increased lithium serum levels.</li> </ul>	<ul style="list-style-type: none"> <li>Ensure service user is aware of the symptoms of lithium toxicity and report them immediately if they occur.</li> </ul>
Anticonvulsants e.g., valproate, carbamazepine, phenytoin	<ul style="list-style-type: none"> <li>Increased neurotoxicity of both drugs at therapeutic doses.</li> <li>Valproate may aggravate tremor.</li> </ul>	<ul style="list-style-type: none"> <li>If neurotoxicity develops, stop lithium.</li> </ul>
Antidepressants e.g., mirtazapine, SSRIs, TCAs and venlafaxine	<ul style="list-style-type: none"> <li>Synergistic antidepressant effect in treatment resistant service users may increase lithium tremor.</li> </ul>	<ul style="list-style-type: none"> <li>Monitor carefully for signs of neurotoxicity.</li> </ul>

	<ul style="list-style-type: none"> <li>• Increase lithium serum level, possible neurotoxicity and serotonergic effects.</li> </ul>	
Antipsychotics	<ul style="list-style-type: none"> <li>• Increased neurotoxicity possible at therapeutic doses in rare cases.</li> <li>• Increased risk of QT prolongation.</li> </ul>	<ul style="list-style-type: none"> <li>• Monitor for risk of QT prolongation.</li> <li>• Monitor for signs of neurotoxicity.</li> </ul>
Calcium channel blockers e.g., diltiazem, verapamil	<ul style="list-style-type: none"> <li>• Increased risk of neurotoxicity with symptoms such as ataxia, confusion and somnolence.</li> </ul>	<ul style="list-style-type: none"> <li>• Monitor for signs of neurotoxicity.</li> </ul>
Sodium bicarbonate containing antacids e.g., Gaviscon®	<ul style="list-style-type: none"> <li>• Excretion of lithium increased by sodium bicarbonate therefore, reduced lithium serum levels.</li> </ul>	<ul style="list-style-type: none"> <li>• Change to an alternative antacid with lower sodium content.</li> </ul>
Theophylline/ aminophylline	<ul style="list-style-type: none"> <li>• Increased excretion of lithium. Reduced lithium serum level. Depressive and/ or manic relapse may occur if the lithium dose is not adjusted.</li> </ul>	<ul style="list-style-type: none"> <li>• Monitor lithium serum levels if theophylline is stopped, started or altered.</li> </ul>

### Drug-Disease Interaction

- If renal impairment exists, avoid use of lithium (if possible) or reduce dose and closely monitor serum-lithium concentration.
- Cardiac disease and conditions with sodium imbalance (e.g., Addison's disease) will require dose reduction or discontinuation. Similarly, in severe diarrhoea and/or vomiting and in concurrent infection (especially if sweating profusely).
- Psoriasis: risk of exacerbation.
- Addison's disease or other conditions with a sodium imbalance and in severely debilitated or dehydrated service users and in severely debilitated or dehydrated service users.
- Avoid in untreated hypothyroidism.
- Use with caution in service users with myasthenia gravis because exacerbation of this disorder has been reported.
- Previous Neuroleptic Malignant Syndrome (NMS) with lithium as reintroduction has led to recurrences of NMS.